Hanmi Science has received external recognition for its achievements in strengthening intellectual property (IP) competitiveness. This acknowledgment reflects the company's ability to protect global research and development (R&D) outcomes and translate them into business competitiveness.
On July 22, Hanmi Group announced that Han Ji-yeon, head of the IP team at Hanmi Science, was awarded a commendation from the Director of the Intellectual Property Office for her contributions to enhancing IP competitiveness during the 80th anniversary celebration of the Korean Patent Attorneys Association held on June 26 in Seocho-gu, Seoul.
In celebration of its 80th anniversary, the Korean Patent Attorneys Association presented government awards and special merit plaques to 43 individuals and organizations, including patent attorneys, companies, research institutions, public organizations, and journalists, who have contributed to the development of patent, trademark, and design systems, as well as technological innovation and industrial competitiveness.
Hanmi Group has been strengthening its IP strategy to connect R&D outcomes to competitive assets by establishing patent strategies, securing rights, supporting overseas applications, and facilitating licensing agreements from the early stages of new drug development. The company continues to secure domestic and international rights and build a portfolio for various R&D assets, including biopharmaceuticals and combination and improved drugs.
Han Ji-yeon is not only active in the domestic IP field but also shares her expertise in international IP exchanges. She participated as a speaker from Korea at the 'AIPPI Trilateral Meeting 2026' held in Guilin, China, in June, where she presented on 'AI & IP: Bridging Innovation, Creation and Protection.'
AIPPI, established in 1897, is an international organization of IP professionals with over 9,000 members across 110 countries. Han discussed issues related to domestic intellectual property rights arising from advancements in artificial intelligence (AI) technology and participated in discussions on regulatory environments and industry responses in various countries.
Hanmi Science leads the direction of new drug development and overseas expansion strategies, including licensing out for Hanmi Pharmaceutical. Han Ji-yeon stated, 'We will continue to strengthen the intellectual property foundation that supports Hanmi's R&D competitiveness and proactively respond to changes in the global IP environment.'
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.